Featured Archives - Page 6 of 22 - Life Sciences Times

Firefly Health Becomes First National Primary Care Provider to Earn NCQA Virtual Care Accreditation

June 4, 2025

Amylyx Pharmaceuticals Earns FDA Fast Track Status for ALS Drug Candidate AMX0114

June 3, 2025

bluebird bio Acquired by Carlyle and SK Capital, Eyes Rapid Expansion Under New Leadership

June 2, 2025

THIS WEEK'S STORIES

ENHERTU Shows Significant Survival Benefit in Advanced Gastric Cancer in Phase 3 Trial

May 31, 2025

Cyberattacks Disrupt Patient Care in Nearly 1 in 5 Healthcare Organizations, Omega Systems Report Finds

June 4, 2025

ImmunAbs Secures FDA Approval to Begin Phase 2 Trial of Novel Myasthenia Gravis Treatment

June 2, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Featured

Firefly Health Becomes First National Primary Care Provider to Earn NCQA Virtual Care Accreditation

Amylyx Pharmaceuticals Earns FDA Fast Track Status for ALS Drug Candidate AMX0114

bluebird bio Acquired by Carlyle and SK Capital, Eyes Rapid Expansion Under New Leadership

ConcertAI Unveils AI-Powered Precision Suite to Revolutionize Oncology Research and Life Sciences

Trinity Life Sciences and Ontada Partner to Enhance Commercial Decision-Making in Community Oncology

Most Read

Ontario Brain Injury Association Warns of Hidden Dangers in Surviving Opioid Overdoses

Canid Raises $10 Million to Modernize Pediatric Vaccine Management and Reduce Burden on Independent Practices

Cyberattacks Disrupt Patient Care in Nearly 1 in 5 Healthcare Organizations, Omega Systems Report Finds

Gore Launches 0.5 mL Silicone-Free Plunger for Ophthalmic Pre-Filled Syringes

EDITOR PICKS

Firefly Health Becomes First National Primary Care Provider to Earn NCQA Virtual Care Accreditation

Amylyx Pharmaceuticals Earns FDA Fast Track Status for ALS Drug Candidate AMX0114

bluebird bio Acquired by Carlyle and SK Capital, Eyes Rapid Expansion Under New Leadership

THIS WEEK'S STORIES

ENHERTU Shows Significant Survival Benefit in Advanced Gastric Cancer in Phase 3 Trial

Cyberattacks Disrupt Patient Care in Nearly 1 in 5 Healthcare Organizations, Omega Systems Report Finds

ImmunAbs Secures FDA Approval to Begin Phase 2 Trial of Novel Myasthenia Gravis Treatment

POPULAR CATEGORY

ABOUT US

FOLLOW US